Clinical Trial Update: Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating oral ibrexafungerp (SCY-078) versus placebo in recurrent vulvovaginal candidiasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Ibrexafungerp (ibrexafungerp)

Snippet

Sponsor: Scynexis, Inc. | Conditions: Recurrent Vulvovaginal Candidiasis | Phase 3 | Status: COMPLETED | Results posted: 2023-06-18